title: [Clinical course of acute respiratory infection and the state of microbiocenosis of upper respiratory tract in pregnant women].
abstract: OBJECTIVE
  Evaluate clinical features of the course of acute respiratory infection (ARI) and the state of microbiocenosis of nasopharynx of pregnant women at gestational term of 14 - 26 weeks.
  
  
  METHODS
  At the stage of outpatient therapy of ARI 49 pregnant women at the gestational term of 14 - 26 weeks were examined: group 1--27 individuals consulting at day 1 and receiving Viferon (gel) intranasally for 10 days, group 2--22 individuals consulting at day 2 - 3 and receiving Viferon (gel and suppositorium). Respiratory viral infection was diagnosed by multiplex PCR. Bacteriologic study of discharge from the middle section of the pharynx was performed by the standard technique.
  
  
  RESULTS
  ARI in group 1 of pregnant women were regarded as mild severity and persisted for an average of 3 days. In group 2 in 13 (59%) of patients ARI of moderate severity was noted and the recovery occurred at day 6. Pyo-inflammatory diseases of ENT organs appeared in 10 (45.4%) of patients. Respiratory infections were determined in 16 (32.7%) of them: coronaviruses--in 5 (10.2%), rhinoviruses--in 3 (6.2%), respiratory syncytial viruses--in 6 (12.3%), parainfluenza (type 2) and influenza A viruses--1 (2%) both, without significant differences between the observed groups. Streptococcus agalactiae, Staphylococcus aureus, Streptococcus mitis, Moraxella catarrhalis, Corynebacterium spp., Streptococcus pyogenes with the predominance of the latter in 36.7% and 60% of cases, respectively, in pregnant women of the group 2 (p < 0.01), were detected in the microflora of the mucous membrane of the nasopharynx.
  
  
  CONCLUSIONS
  Viferon preparation therapy prescribed at day 1 of outpatient visit of pregnant women may promote mild course o fARI and prophylaxis of complications of upper respiratory tract.
authors.forename: M P
authors.initials: MP
authors.lastname: Kostinov
authors.forename: A K
authors.initials: AK
authors.lastname: Meshcheriakova
authors.forename: E P
authors.initials: EP
authors.lastname: Foshina
authors.forename: D A
authors.initials: DA
authors.lastname: Tarbaeva
authors.forename: A A
authors.initials: AA
authors.lastname: Savis'ko
authors.forename: E V
authors.initials: EV
authors.lastname: Zaĭtseva
mesh_terms: D000208:Acute Disease; D000281:Administration, Intranasal; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000821:virology; D005260:Female; D006090:Gram-Negative Bacteria / Q000502:physiology; D006094:Gram-Positive Bacteria / Q000502:physiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D060885:Multiplex Polymerase Chain Reaction; D009305:Nasopharynx / Q000382:microbiology / Q000821:virology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control* / Q000821:virology; D011262:Pregnancy Trimester, Second; D011994:Recombinant Proteins / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000821:virology; D012720:Severity of Illness Index; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000821:virology; D014780:Viruses / Q000254:growth & development
chemical_list: D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins